
Journalist - Indian pharma & healthcare. Views own [email protected]
Thane West, India
Joined April 2009
- Tweets30.7K
- Following476
- Followers13.6K
- Likes14.4K
Pinned Tweet
2024 wrap up time! #Thread some good, some sobering and some that were tough. In January, Rajeev Raghuvanshi, India’s DCGI laid out the roadmap for the big changes in an exclusive Q&A. An ongoing task and much is expected:
economictimes.indiatimes.com…
Vikas Dandekar retweeted
We’re making a personalized cancer vaccine for Yash, a 34 year-old pancreatic cancer patient, in the open with his consent.
We want external experts to review our design and make their own contributions before we manufacture it at the RNA Foundry.
RNAFoundry.com/yash
Vikas Dandekar retweeted
Today's ET podcast discusses the oncology drug pricing mess in India.
@VikasReports slices the market correctly between generic & patented medicines.
What is important is to ASK why generic medicines have such crazy margins? Focus on that 🙂
youtu.be/OURK7DZygDU
Vikas Dandekar retweeted
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:
Vikas Dandekar retweeted
The most expensive part of a hospital bill may never touch the hospital at all.
A patient admitted for care has no way of knowing whether the price on a medical consumable reflects its actual cost or a markup fixed long before it ever reached the ward. That gap in information is, at its core, a public health issue.
A survey of hospital consumables in Maharashtra found an IV infusion set with a trade price of ₹11.05 carrying a printed MRP of ₹325 ; a markup of 2,841%. A syringe procured at ₹6.75 carried an MRP of ₹57.20. A catheter procured at ₹29.41 carried an MRP of ₹310.
These are not elective purchases. Patients cannot compare prices, seek alternatives, or question a number printed on a box while receiving care and the MRP itself is often fixed upstream by manufacturers and distributors, disconnected from the trade price by a wide, unexplained margin. The result is a system where the party bearing the cost has the least information to evaluate it.
The regulatory gap is structural: scheduled medicines are capped under the Drugs (Prices Control) Order, 2013. Most medical devices and consumables are not leaving both the pricing and the information around it almost entirely unmonitored.
A review of these findings and clear guidelines on the permissible gap between trade procurement price and declared MRP have been recommended to the Department of Pharmaceuticals and the NPPA ; a step toward closing not just a pricing gap, but the information gap patients are left to bear alone.
#PublicHealth #GoodGovernance #Leadership #TukaramMundhe
moneycontrol.com/news/busine…
Vikas Dandekar retweeted
BKC connector deep red, Freeway deep red. Bangalore - Mumbai highway jammed out. Ditto for Western Expressway. And you claim you are investing in infrastructure @Dev_Fadnavis in #Mumbai
Travel like a normal citizen and see how the great @MumbaiPolice manages traffic at peak office hours. @TawdeRitu step out of your bungalow once. One Coastal Rd in 10 yrs, and maximum city has become Shanghai? #mumbaitraffic – at Mumbai, India
Vikas Dandekar retweeted
In a defining moment at #ETWLF, Narendra Modi, Prime Minister of India, delivered the keynote address, sharing his vision for India’s growth journey and the country’s expanding role on the global stage. His address placed India’s ambitions firmly within the global conversation before an audience of business and policy leaders from around the world.
@narendramodi
#ETWorldLeadersForum
@specfinancegfty @Visa_IND @Suzlon @casagrandhomes @EconomicTimes
Vikas Dandekar retweeted
Sharing my latest investigation into the #Kota deaths-a story that is not just about a spurious drug but about a 3-yr regulatory trail that nobody stopped.
And a law-Section 27A-that promises life imprisonment, yet has delivered nothing to the families left behind.
Tragic to see this. Least that could be expected from the BMC is to prepare and prevent such disasters. We have a long season ahead. Prayers for the family who lost their dear child 🙏
#Thread Year-old pics of the tree that fell on a school bus on 11th road, #Chembur killing one child and injuring others. Shared with BMC at the time by a citizen in the vicinity with regards to the concretisation(1) @mybmc @mybmcWardMW @mayor_mumbai @TawdeRitu @AshwiniBhide
Vikas Dandekar retweeted
#Thread Year-old pics of the tree that fell on a school bus on 11th road, #Chembur killing one child and injuring others. Shared with BMC at the time by a citizen in the vicinity with regards to the concretisation(1) @mybmc @mybmcWardMW @mayor_mumbai @TawdeRitu @AshwiniBhide
Vikas Dandekar retweeted
The initial euphoria over weight-loss drugs is starting to wear off in India. Several homegrown drugmakers are quietly paring sales targets, underscoring tepid prescription growth and weaker-than-expected patient retention.
@VikasReports and I write in today’s @EconomicTimes
India is a weird market. With obesity rates shooting up, I'd have bet on the sales of generic GLP-1s exploding once their patents expired. They now cost about Rs 1,000–2,500 a month, and there's growing evidence pointing to benefits well beyond weight loss, including cardiovascular, metabolic, and liver health.
Yet, generic drugmakers are quietly cutting their sales targets by 25–30%. At Rs 1,000–2,500 a month, it's cheaper than a gym membership. The real problem seems to be retention. GLP-1s are injectables, and you have to keep taking them. If you stop, you gain back the lost weight. It seems like asking someone to stay on a weekly injection indefinitely is a much harder sell.
A few other friction points:
For a variety of reasons, Indians haven't taken to GLP-1s with the same enthusiasm as Western populations. Could it be because Indian physicians are conservative when it comes to prescribing newer drugs?
Self-injecting is a pain for most people, and that friction and inertia might be stopping them from starting in the first place.
Given that there are now GLP-1 pills, I'm wondering if the adoption curve will change.
Vikas Dandekar retweeted
31,000+ heart surgeries. 99.8% success rate.
@DrRamakantPanda, founder of Asian Heart Institute, says nearly 80% of younger cardiac patients he sees come from IT and finance.
Listen in to his expansive conversation with ET’s pharma editor @VikasReports and @RicaB_ET on stress, sleep, heart disease, why excellence can't be franchised, AI-driven healthcare, and the patience behind a perfect wildlife photograph.
Links in thread
Vikas Dandekar retweeted
Super duper proud to share we won the @sopasia award for Excellence in Audio Reporting…again!
We won for an investigative audio deep dive by me, @diarekhiET and @VikasReports on India-made spurious cough syrups that have been causing children’s deaths over several years in India and other countries.
The latest trigger was the deaths by a syrup called Coldrif, made by TN-based Sresan Pharma which was laced with high amounts of diethylene glycol, an industrial chemical.
We spoke to mourning fathers, doctors, the cop investigating the case, health activists and pored through probe reports (current and previous) and legal annals. They led us to a string of previous cases, names of spurious medicine makers still operating undeterred in India, lax laws and implementability and shockingly different standards for drugs consumed locally and exported.
Thank you @Preddy85 @d_s_thakur @drgilada Pramod Verma, Dr Arvind Bagga for your voices. I hope the children’s parents have healed somewhat. There’s no other way…
This is the link to the episode: m.economictimes.com/news/mor…
PS: This is our second win…the first one was in 2024
For this: m.economictimes.com/news/mor…
@sruthijith @arijitbarman76
🏆 Audio Reporting - Award for Excellence - Regional/Local group goes to @EconomicTimes! A compelling investigative report calling urgent attention to a shocking pharmaceutical scandal: Indian-made cough syrup that killed children across multiple countries. Congratulations! #SOPAwards2026
🎙
economictimes.indiatimes.com…
Vikas Dandekar retweeted
🏆 Audio Reporting - Award for Excellence - Regional/Local group goes to @EconomicTimes! A compelling investigative report calling urgent attention to a shocking pharmaceutical scandal: Indian-made cough syrup that killed children across multiple countries. Congratulations! #SOPAwards2026
🎙
economictimes.indiatimes.com…
Vikas Dandekar retweeted
Why no one is talking about this? In Himachal pradesh almost 2 lakh people are affected by antibiotic resistance. Around 600 factories are dumping pharma waste without any care. Most of them are dumping directly in rivers. Sirsa river TDS is cross 1000. Thank you Dainik bhaskar for covering this.
While no formal pullback has been announced, industry voices have grown louder. Longer-term relief, most agree, lies in revised rates and a more predictable payment cycle.
economictimes.indiatimes.com…
@VikasReports
Vikas Dandekar retweeted
Sun Pharma’s $11.75B Organon deal is India’s biggest pharma bet.
Women’s health, biosimilars and 50 established brands can catapult Sun to a global leader.
But scale comes with leverage and complexity. Integration, cash flows, and execution will matter more than strategy slides.
I speak to @arijitbarman76 and @VikasReports who scooped every bit of the story: discussion to fruition
Vikas Dandekar retweeted
Already seeing people claiming credit but Sun Pharma’s high voltage acquisition of Organon, the biggest M&A by an Indian company since Tata’s purchase of Corus, was an exclusive broken by Arijit and Vikas in the 19 Jan edition of ET. They got every follow up story right and correctly called the acquisition going through in last night’s edition. Months of dogged pursuit.
When it comes to Arijit’s track record in big ticket M&A, I’m reminded of what Tyson said about Ali during a heartwarming meeting of the legends: “Every head must bow, every tongue must confess, he’s the greatest of all time”.
Take a bow, comrades. @arijitbarman76 and pharma don @VikasReports
Vikas Dandekar retweeted
Replying to @SunPharma_Live
@SunPharma_Live set to acquire Organon for $12.5 bn, its biggest till date. @EconomicTimes exclusive @VikasReports @ETPharma
economictimes.indiatimes.com…
Vikas Dandekar retweeted
Winners of the Oscars of business #ETAwards
Business Leader: Sajjan Jindal ‘steels’ the spotlight…
Company of the Year: Airtel gets connected
Lifetime Achievement: Cyrus Poonawalla gives excellence a perfect shot
K P Singh builds it brick by brick
Business Reformer : Chandrababu Naidu scripts reform…
Global Indian: Neal Mohan hits play globally
Businesswoman: Vibha Padalkar secures the future
Vikas Dandekar retweeted
Will they, won't they? We have been on this story since January. Now as it reaches the last leg, we wait for the final . If there is one man it's #dilipsanghvi and one co @SunPharma_Live that can dare to do something bold as @Organon Our #newsbreak in the
@EconomicTimes @eqt #gruenthal
@VikasReports
m.economictimes.com/industry…





























